To test the effects of TACC3 inhibition on the growth of tumors with CA in vivo, we performed CRISPR Cas9-mediated knockout of TACC3 in MDA-MB-231 cells in addition to JIMT-1 cells (Fig. 2C) and validated the TACC3 depletion by Western blotting (Fig. 6A). This evidence concerns the gene TACC3 and cancer.